文献速递湿疹皮炎与荨麻疹

德国H1抗组胺药难治性慢性自发性荨麻疹的社会经济负担

The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-05-11

该研究基于InGef数据库和AWARE研究数据,量化德国H1抗组胺药难治性慢性自发性荨麻疹的流行病学及社会经济负担。疾病控制不佳(UCT<12)患者受损更重,负担更高。

要点

  • 德国2018年20岁以上H1-AH难治性CSU患者超过203,000例。
  • 归因于该病的带薪与无薪工作损失工时合计超1亿小时。

核心结论

  • H1抗组胺药难治性慢性自发性荨麻疹在德国造成显著社会经济负担,对个体日常生活和社会整体影响巨大。

研究设计与样本

  • 基于InGef研究数据库匿名数据确定CSU年龄性别特异性患病率及H1-AH难治比例,并将AWARE研究观察到的WPAI外推至德国H1-AH难治性CSU人群计算工时损失,分别用人资本法和摩擦成本法货币化带薪与无薪工作生产力损失。

主要发现

  • 2018年德国20岁及以上H1-AH难治性CSU患者超过203,000例。
  • 归因于H1-AH难治性CSU的带薪与无薪工作损失工时合计超过1亿小时。
  • UCT评分<12的疾病控制不佳患者比控制良好患者更易出现高损害,导致更高社会经济负担。

关键数值与推荐

  • 疾病控制以荨麻疹控制试验(UCT)评估,UCT评分<12提示控制不佳。
  • 带薪工作生产力损失用人资本法货币化,无薪工作生产力损失用摩擦成本法货币化。

临床怎么用

  • 临床评估H1-AH难治性CSU时应关注疾病控制水平(UCT<12),控制不佳者损害更重、社会经济负担更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND STUDY AIM: Data from the AWARE study (A Worldwide Antihistamine-Refractory chronic urticaria patient Evaluation) illustrate a substantial disease burden in German patients with H1-antihistamine (-H1-AH)-refractory chronic spontaneous urticaria (CSU). Detrimental effects on patients' quality of life, poor disease control and impairment in the ability to work and perform other daily activities are reported. Based on these findings, this study aims to quantify the epidemiological and socio-economic burden of H1-AH-refractory CSU in Germany. METHODS: To determine the epidemiological burden of H1-AH-refractory CSU, the age- and gender-specific prevalence of CSU and the proportion of H1-AH-refractory patients in Germany anonymized data from the InGef research database have been used. In a second step, the socio-economic burden in terms of lost numbers of hours in paid and unpaid work was calculated by extrapolating the age- and gender-specific work productivity and activity impairment (WPAI) observed in AWARE to the H1-AH-refractory CSU population in Germany. Finally, productivity losses in paid and unpaid work were monetized using the human capital and the friction cost approach respectively. Moreover, socio-economic burden was calculated depending on symptom control of the patients (measured by urticaria control test [UCT]). RESULTS: In Germany, over 203,000 patients (20 years or older) had H1-AH-refractory CSU in 2018. The avoided lost paid and unpaid work hours attributable to H1-AH-refractory CSU summed up to over 100 million. Overall, the socio-economic burden of H1-AH-refractory CSU in monetary terms was evaluated at € 2.2 billion and the majority of this was due to unpaid work loss. Patients with poor disease control, as indicated by UCT score < 12, were more likely to suffer from high impairment than patients with controlled disease, resulting in a higher socio-economic burden. CONCLUSIONS: The results of our analyses picture the substantial socio-economic burden of H1-AH-refractory CSU and therefore the tremendous impact it has on daily lives of individuals and society overall.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Augustin M, Beier D, Branner J, et al. The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany. J Eur Acad Dermatol Venereol. 2024. PMID: 38733261. doi:10.1111/jdv.20071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。